U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07142057) titled 'An Observational Study on the Impact of the 23-valent Pneumonia Vaccine on Lung Cancer Patients' on Aug. 19.

Brief Summary: To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.

Study Start Date: Sept. 01

Study Type: OBSERVATIONAL

Condition: LUNG CANCER

Intervention: BIOLOGICAL: 23-valent pneumococcal vaccine

Receive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine

Recruitment Status: NOT_YET_RECRUITING

Sponsor: The First Affiliate...